Thyrocare Technologies Bonus Record Date on Nov 28: Declared 2:1 Bonus Issue

Thyrocare Technologies Ltd has set Nov 28, 2025, as the record date for its 2:1 bonus. This means that every eligible shareholder will be receiving 1 free share for every 2 shares held. 

Thyrocare Technologies Ltd said in an exchange filing, “The shareholders have approved the issuance of bonus equity shares in the ratio of 2:1 i.e., 2 (two) bonus equity shares of face value Rs. 10 (Rupees ten only) each for every 1 (one) equity share.”

Further, the company announced that the deemed date of allotment has been set for December 1, 2025, and the bonus shares will be available for trading on the next working day on December 2, 2025.

What Does Thyrocare Technologies Bonus Record Date Mean for Shareholders?

As Thyrocare Technologies has set Nov 28 as the record date for the bonus issue, meaning that Nov 27 was the last day to buy Thyrocare Technologies shares to become eligible for the bonus issue. Further, any shares bought on or after Nov 28 (record date), won't be eligible for the bonus shares due to the T+1 settlement rule.

Also Read: RBI Plans Weekly Credit Score Updates - What Does This Mean for Borrowers?

Thyrocare Technologies Management Take on Q2FY26 Earnings 

“We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India” – Rahul Guha, MD & CEO, Thyrocare Technologies Ltd.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.